1
|
Lüscher TF, Wenzl FA, D'Ascenzo F, Friedman PA, Antoniades C. Artificial intelligence in cardiovascular medicine: clinical applications. Eur Heart J 2024; 45:4291-4304. [PMID: 39158472 DOI: 10.1093/eurheartj/ehae465] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/18/2024] [Revised: 06/07/2024] [Accepted: 07/03/2024] [Indexed: 08/20/2024] Open
Abstract
Clinical medicine requires the integration of various forms of patient data including demographics, symptom characteristics, electrocardiogram findings, laboratory values, biomarker levels, and imaging studies. Decision-making on the optimal management should be based on a high probability that the envisaged treatment is appropriate, provides benefit, and bears no or little potential harm. To that end, personalized risk-benefit considerations should guide the management of individual patients to achieve optimal results. These basic clinical tasks have become more and more challenging with the massively growing data now available; artificial intelligence and machine learning (AI/ML) can provide assistance for clinicians by obtaining and comprehensively preparing the history of patients, analysing face and voice and other clinical features, by integrating laboratory results, biomarkers, and imaging. Furthermore, AI/ML can provide a comprehensive risk assessment as a basis of optimal acute and chronic care. The clinical usefulness of AI/ML algorithms should be carefully assessed, validated with confirmation datasets before clinical use, and repeatedly re-evaluated as patient phenotypes change. This review provides an overview of the current data revolution that has changed and will continue to change the face of clinical medicine radically, if properly used, to the benefit of physicians and patients alike.
Collapse
Affiliation(s)
- Thomas F Lüscher
- Royal Brompton and Harefield Hospitals, London, UK
- National Heart and Lung Institute, Imperial College London, UK
- Cardiovascular Academic Group, King's College, London, UK
- Center for Molecular Cardiology, University of Zurich, Wagistrasse 12, 8952 Schlieren - Zurich, Switzerland
| | - Florian A Wenzl
- Center for Molecular Cardiology, University of Zurich, Wagistrasse 12, 8952 Schlieren - Zurich, Switzerland
- National Disease Registration and Analysis Service, NHS, London, UK
- Department of Cardiovascular Sciences, University of Leicester, Leicester, UK
- Department of Clinical Sciences, Karolinska Institutet, Stockholm, Sweden
| | - Fabrizio D'Ascenzo
- Division of Cardiology, Cardiovascular and Thoracic Department, Città della Salute e della Scienza Hospital, Turin, Italy
| | - Paul A Friedman
- Department of Cardiovascular Medicine, Mayo Clinic and Mayo Foundation, Rochester, MN, USA
| | - Charalambos Antoniades
- Acute Multidisciplinary Imaging and Interventional Centre, RDM Division of Cardiovascular Medicine, University of Oxford, Headley Way, Headington, Oxford OX39DU, UK
| |
Collapse
|
2
|
Szymański P, Rademakers F, Fraser AG. The Artificial Intelligence Act approved by the EU: the difficult dialogue between the black box and the cardiologist. Eur Heart J 2024; 45:2686-2688. [PMID: 38848102 DOI: 10.1093/eurheartj/ehae281] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 08/10/2024] Open
Affiliation(s)
- Piotr Szymański
- Clinical Cardiology Center, National Institute of Medicine MSWiA, Wołoska 137, 02-507 Warsaw, Poland
- Center for Postgraduate Medical Education, Marymoncka 99, 01-813 Warsaw, Poland
| | | | - Alan G Fraser
- Department of Cardiology, University Hospital of Wales, Cardiff, UK
| |
Collapse
|
3
|
Farah L, Borget I, Martelli N, Vallee A. Suitability of the Current Health Technology Assessment of Innovative Artificial Intelligence-Based Medical Devices: Scoping Literature Review. J Med Internet Res 2024; 26:e51514. [PMID: 38739911 PMCID: PMC11130781 DOI: 10.2196/51514] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/02/2023] [Revised: 12/17/2023] [Accepted: 12/28/2023] [Indexed: 05/16/2024] Open
Abstract
BACKGROUND Artificial intelligence (AI)-based medical devices have garnered attention due to their ability to revolutionize medicine. Their health technology assessment framework is lacking. OBJECTIVE This study aims to analyze the suitability of each health technology assessment (HTA) domain for the assessment of AI-based medical devices. METHODS We conducted a scoping literature review following the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) methodology. We searched databases (PubMed, Embase, and Cochrane Library), gray literature, and HTA agency websites. RESULTS A total of 10.1% (78/775) of the references were included. Data quality and integration are vital aspects to consider when describing and assessing the technical characteristics of AI-based medical devices during an HTA process. When it comes to implementing specialized HTA for AI-based medical devices, several practical challenges and potential barriers could be highlighted and should be taken into account (AI technological evolution timeline, data requirements, complexity and transparency, clinical validation and safety requirements, regulatory and ethical considerations, and economic evaluation). CONCLUSIONS The adaptation of the HTA process through a methodological framework for AI-based medical devices enhances the comparability of results across different evaluations and jurisdictions. By defining the necessary expertise, the framework supports the development of a skilled workforce capable of conducting robust and reliable HTAs of AI-based medical devices. A comprehensive adapted HTA framework for AI-based medical devices can provide valuable insights into the effectiveness, cost-effectiveness, and societal impact of AI-based medical devices, guiding their responsible implementation and maximizing their benefits for patients and health care systems.
Collapse
Affiliation(s)
- Line Farah
- Innovation Center for Medical Devices Department, Foch Hospital, Suresnes, France
- Groupe de Recherche et d'accueil en Droit et Economie de la Santé Department, University Paris-Saclay, Orsay, France
| | - Isabelle Borget
- Groupe de Recherche et d'accueil en Droit et Economie de la Santé Department, University Paris-Saclay, Orsay, France
- Department of Biostatistics and Epidemiology, Gustave Roussy, University Paris-Saclay, Villejuif, France
- Oncostat U1018, Inserm, Équipe Labellisée Ligue Contre le Cancer, University Paris-Saclay, Villejuif, France
| | - Nicolas Martelli
- Groupe de Recherche et d'accueil en Droit et Economie de la Santé Department, University Paris-Saclay, Orsay, France
- Pharmacy Department, Georges Pompidou European Hospital, Paris, France
| | - Alexandre Vallee
- Department of Epidemiology and Public Health, Foch Hospital, Suresnes, France
| |
Collapse
|
4
|
Biccirè FG, Mannhart D, Kakizaki R, Windecker S, Räber L, Siontis GCM. Automatic assessment of atherosclerotic plaque features by intracoronary imaging: a scoping review. Front Cardiovasc Med 2024; 11:1332925. [PMID: 38742173 PMCID: PMC11090039 DOI: 10.3389/fcvm.2024.1332925] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/03/2023] [Accepted: 04/01/2024] [Indexed: 05/16/2024] Open
Abstract
Background The diagnostic performance and clinical validity of automatic intracoronary imaging (ICI) tools for atherosclerotic plaque assessment have not been systematically investigated so far. Methods We performed a scoping review including studies on automatic tools for automatic plaque components assessment by means of optical coherence tomography (OCT) or intravascular imaging (IVUS). We summarized study characteristics and reported the specifics and diagnostic performance of developed tools. Results Overall, 42 OCT and 26 IVUS studies fulfilling the eligibility criteria were found, with the majority published in the last 5 years (86% of the OCT and 73% of the IVUS studies). A convolutional neural network deep-learning method was applied in 71% of OCT- and 34% of IVUS-studies. Calcium was the most frequent plaque feature analyzed (26/42 of OCT and 12/26 of IVUS studies), and both modalities showed high discriminatory performance in testing sets [range of area under the curve (AUC): 0.91-0.99 for OCT and 0.89-0.98 for IVUS]. Lipid component was investigated only in OCT studies (n = 26, AUC: 0.82-0.86). Fibrous cap thickness or thin-cap fibroatheroma were mainly investigated in OCT studies (n = 8, AUC: 0.82-0.94). Plaque burden was mainly assessed in IVUS studies (n = 15, testing set AUC reported in one study: 0.70). Conclusion A limited number of automatic machine learning-derived tools for ICI analysis is currently available. The majority have been developed for calcium detection for either OCT or IVUS images. The reporting of the development and validation process of automated intracoronary imaging analyses is heterogeneous and lacks critical information. Systematic Review Registration Open Science Framework (OSF), https://osf.io/nps2b/.Graphical AbstractCentral Illustration.
Collapse
Affiliation(s)
| | | | | | | | | | - George C. M. Siontis
- Department of Cardiology, Bern University Hospital, University of Bern, Bern, Switzerland
| |
Collapse
|
5
|
Martina MR, Park C, Alastruey J, Bruno RM, Climie R, Dogan S, Tuna BG, Jerončić A, Manouchehri M, Panayiotou AG, Tamarri S, Terentes-Printzios D, Testa M, Triantafyllou A, Mayer CC, Bianchini E. Medical device regulation in vascular ageing assessment: a VascAgeNet survey exploring knowledge and perception. Expert Rev Med Devices 2024; 21:335-347. [PMID: 38557297 DOI: 10.1080/17434440.2024.2334931] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/25/2023] [Accepted: 03/15/2024] [Indexed: 04/04/2024]
Abstract
BACKGROUND Regulation has a key role for medical devices throughout their lifecycle aiming to guarantee effectiveness and safety for users. Requirements of Regulation (EU) 2017/745 (MDR) have an impact on novel and previously approved systems. Identification of key stakeholders' needs can support effective implementation of MDR improving the translation to clinical practice of vascular ageing assessment. The aim of this work is to explore knowledge and perception of medical device regulatory framework in vascular ageing field. RESEARCH DESIGN AND METHODS A survey was developed within VascAgeNet and distributed in the community by means of the EUSurvey platform. RESULTS Results were derived from 94 participants (27% clinicians, 62% researchers, 11% companies) and evidenced mostly a fair knowledge of MDR (despite self-judged as poor by 51%). Safety (83%), validation (56%), risk management (50%) were considered relevant and associated with the regulatory process. Structured support and regulatory procedures connected with medical devices in daily practice at the institutional level are lacking (only 33% report availability of a regulatory department). CONCLUSIONS Regulation was recognized relevant by the VascAgeNet community and specific support and training in medical device regulatory science was considered important. A direct link with the regulatory sector is not yet easily available.
Collapse
Affiliation(s)
| | - Chloe Park
- University College London (UCL), London, UK
| | - Jordi Alastruey
- Department of Biomedical Engineering, King's College London, London, UK
| | - Rosa Maria Bruno
- PARCC (Paris Cardiovascular Research Center, Inserm U970), Université Paris Cité, Inserm, Paris, France
| | - Rachel Climie
- Menzies Institute for Medical Research, University of Tasmania, Hobart, Australia
| | - Soner Dogan
- Department of Medical Biology, Yeditepe University, School of Medicine, Istanbul, Turkiye
| | - Bilge Guvenc Tuna
- Department of Biophysics, Yeditepe University, School of Medicine, Istanbul, Turkiye
| | - Ana Jerončić
- Department of Research in Biomedicine and Health & Laboratory of Vascular Aging and Cardiovascular Prevention, University of Split School of Medicine, Split, Croatia
| | | | - Andrie G Panayiotou
- Department of Rehabilitation Sciences, Cyprus University of Technology, Limassol, Cyprus
| | | | - Dimitrios Terentes-Printzios
- First Department of Cardiology, National and Kapodistrian University of Athens, Medical School, Hippokration Hospital, Athens, Greece
| | | | - Areti Triantafyllou
- 3rd Clinic of Internal Medicine, Papageorgiou GH, Aristotle University of Thessaloniki, Thessaloniki, Greece
| | - Christopher C Mayer
- AIT Austrian Institute of Technology GmbH, Center for Health & Bioresources, Medical Signal Analysis, Vienna, Austria
| | - Elisabetta Bianchini
- Institute of Clinical Physiology - Italian National Research Council (CNR-IFC), Pisa, Italy
| |
Collapse
|
6
|
Campion JR, O'Connor DB, Lahiff C. Human-artificial intelligence interaction in gastrointestinal endoscopy. World J Gastrointest Endosc 2024; 16:126-135. [PMID: 38577646 PMCID: PMC10989254 DOI: 10.4253/wjge.v16.i3.126] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/31/2023] [Revised: 01/18/2024] [Accepted: 02/23/2024] [Indexed: 03/14/2024] Open
Abstract
The number and variety of applications of artificial intelligence (AI) in gastrointestinal (GI) endoscopy is growing rapidly. New technologies based on machine learning (ML) and convolutional neural networks (CNNs) are at various stages of development and deployment to assist patients and endoscopists in preparing for endoscopic procedures, in detection, diagnosis and classification of pathology during endoscopy and in confirmation of key performance indicators. Platforms based on ML and CNNs require regulatory approval as medical devices. Interactions between humans and the technologies we use are complex and are influenced by design, behavioural and psychological elements. Due to the substantial differences between AI and prior technologies, important differences may be expected in how we interact with advice from AI technologies. Human–AI interaction (HAII) may be optimised by developing AI algorithms to minimise false positives and designing platform interfaces to maximise usability. Human factors influencing HAII may include automation bias, alarm fatigue, algorithm aversion, learning effect and deskilling. Each of these areas merits further study in the specific setting of AI applications in GI endoscopy and professional societies should engage to ensure that sufficient emphasis is placed on human-centred design in development of new AI technologies.
Collapse
Affiliation(s)
- John R Campion
- Department of Gastroenterology, Mater Misericordiae University Hospital, Dublin D07 AX57, Ireland
- School of Medicine, University College Dublin, Dublin D04 C7X2, Ireland
| | - Donal B O'Connor
- Department of Surgery, Trinity College Dublin, Dublin D02 R590, Ireland
| | - Conor Lahiff
- Department of Gastroenterology, Mater Misericordiae University Hospital, Dublin D07 AX57, Ireland
- School of Medicine, University College Dublin, Dublin D04 C7X2, Ireland
| |
Collapse
|
7
|
Wu Q, Li X, Li L, Yan O, He Q. Analysis of factors affecting ultrasound examination time: A quantitative study. Technol Health Care 2024; 32:1015-1027. [PMID: 37545283 DOI: 10.3233/thc-230406] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 08/08/2023]
Abstract
BACKGROUND Numerous studies have focused on reducing patient absences and effectively scheduling exams. However, very few studies have analyzed the factors influencing examination time and predicted examination time. OBJECTIVES To investigate the factors affecting ultrasound examination visit length and provide a reference for interventions to optimize ultrasound appointments. METHODS This cross-sectional study was conducted at a fertility clinic in China. Ultrasound examination time and clinical characteristics were obtained from the electronic records. Univariate and multivariate analyses used 33,432 patients who attended our clinic center between August 1 and October 30, 2018. A quantile regression model was constructed to examine associations between ultrasound examination time and statistically significant variables in the univariate analysis. RESULTS Of the 33,432 patients included in this study, 29,085 (87%) were female and 4,347 (13%) were male. Their mean examination time was 6 ± 3 minutes. The doctor's title and gender, equipment, and patient's age, examination site, gender, and origin were all statistically significant. Physical examination and outpatient clinic patients had shorter examination times than inpatients. Female physicians had longer examination times than male physicians. Examination time was positively correlated with thyroid, breast, liver, gallbladder, spleen, pancreas, kidney, heart, vascular, adrenal, gynecological, early pregnancy, nuchal translucency, prostate, scrotum, and mid-to-late pregnancy fetal sites. Moreover, NT and mid-to-late pregnancy fetal sites showed a clear and continuous positive trend with increasing examination time. CONCLUSION The length of the ultrasound examination was correlated with the examination site, physician title, physician gender, patient age, patient gender, patient origin, and instrumentation. The reliability of inspection time predicted by variables such as the physicians' title, sex, sites examined, and the number of sites examined was higher when they were longer.
Collapse
Affiliation(s)
- Qingqing Wu
- Reproductive and Genetic Hospital of CITIC-Xiangya, Changsha, Hunan, China
- Clinical Research Center For Reproduction and Genetics In Hunan Province, Changsha, Hunan, China
| | - Xihong Li
- Reproductive and Genetic Hospital of CITIC-Xiangya, Changsha, Hunan, China
- Clinical Research Center For Reproduction and Genetics In Hunan Province, Changsha, Hunan, China
| | - Li Li
- Reproductive and Genetic Hospital of CITIC-Xiangya, Changsha, Hunan, China
- Clinical Research Center For Reproduction and Genetics In Hunan Province, Changsha, Hunan, China
| | - Ouyang Yan
- Reproductive and Genetic Hospital of CITIC-Xiangya, Changsha, Hunan, China
- Clinical Research Center For Reproduction and Genetics In Hunan Province, Changsha, Hunan, China
| | - Qingwen He
- Reproductive and Genetic Hospital of CITIC-Xiangya, Changsha, Hunan, China
- Clinical Research Center For Reproduction and Genetics In Hunan Province, Changsha, Hunan, China
| |
Collapse
|
8
|
Pinton P. Impact of artificial intelligence on prognosis, shared decision-making, and precision medicine for patients with inflammatory bowel disease: a perspective and expert opinion. Ann Med 2024; 55:2300670. [PMID: 38163336 PMCID: PMC10763920 DOI: 10.1080/07853890.2023.2300670] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/17/2023] [Accepted: 12/27/2023] [Indexed: 01/03/2024] Open
Abstract
INTRODUCTION Artificial intelligence (AI) is expected to impact all facets of inflammatory bowel disease (IBD) management, including disease assessment, treatment decisions, discovery and development of new biomarkers and therapeutics, as well as clinician-patient communication. AREAS COVERED This perspective paper provides an overview of the application of AI in the clinical management of IBD through a review of the currently available AI models that could be potential tools for prognosis, shared decision-making, and precision medicine. This overview covers models that measure treatment response based on statistical or machine-learning methods, or a combination of the two. We briefly discuss a computational model that allows integration of immune/biological system knowledge with mathematical modeling and also involves a 'digital twin', which allows measurement of temporal trends in mucosal inflammatory activity for predicting treatment response. A viewpoint on AI-enabled wearables and nearables and their use to improve IBD management is also included. EXPERT OPINION Although challenges regarding data quality, privacy, and security; ethical concerns; technical limitations; and regulatory barriers remain to be fully addressed, a growing body of evidence suggests a tremendous potential for integration of AI into daily clinical practice to enable precision medicine and shared decision-making.
Collapse
Affiliation(s)
- Philippe Pinton
- Clinical and Translational Sciences, Ferring Pharmaceuticals, Kastrup, Denmark
| |
Collapse
|
9
|
Chen C, Chen Z, Luo W, Xu Y, Yang S, Yang G, Chen X, Chi X, Xie N, Zeng Z. Ethical perspective on AI hazards to humans: A review. Medicine (Baltimore) 2023; 102:e36163. [PMID: 38050218 PMCID: PMC10695628 DOI: 10.1097/md.0000000000036163] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/05/2023] [Accepted: 10/26/2023] [Indexed: 12/06/2023] Open
Abstract
This article explores the potential ethical hazards of artificial intelligence (AI) on society from an ethical perspective. We introduce the development and application of AI, emphasizing its potential benefits and possible negative impacts. We particularly examine the application of AI in the medical field and related ethical and legal issues, and analyze potential hazards that may exist in other areas of application, such as autonomous driving, finance, and security. Finally, we offer recommendations to help policymakers, technology companies, and society as a whole address the potential hazards of AI. These recommendations include strengthening regulation and supervision of AI, increasing public understanding and awareness of AI, and actively exploring how to use the advantages of AI to achieve a more just, equal, and sustainable social development. Only by actively exploring the advantages of AI while avoiding its negative impacts can we better respond to future challenges.
Collapse
Affiliation(s)
- Changye Chen
- The First Affiliated Hospital of Shenzhen University, Shenzhen University, Shenzhen, Guangdong, China
| | - Ziyu Chen
- The First Affiliated Hospital of Shenzhen University, Shenzhen University, Shenzhen, Guangdong, China
| | - Wenyu Luo
- The First Affiliated Hospital of Shenzhen University, Shenzhen University, Shenzhen, Guangdong, China
- The School of Public Health, Guilin Medical University, Gui Lin, Guangxi, China
| | - Ying Xu
- The First Affiliated Hospital of Shenzhen University, Shenzhen University, Shenzhen, Guangdong, China
| | - Sixia Yang
- The First Affiliated Hospital of Shenzhen University, Shenzhen University, Shenzhen, Guangdong, China
| | - Guozhao Yang
- The First Affiliated Hospital of Shenzhen University, Shenzhen University, Shenzhen, Guangdong, China
| | - Xuhong Chen
- The First Affiliated Hospital of Shenzhen University, Shenzhen University, Shenzhen, Guangdong, China
| | - Xiaoxia Chi
- The First Affiliated Hospital of Shenzhen University, Shenzhen University, Shenzhen, Guangdong, China
| | - Ni Xie
- The First Affiliated Hospital of Shenzhen University, Shenzhen University, Shenzhen, Guangdong, China
| | - Zhuoying Zeng
- The First Affiliated Hospital of Shenzhen University, Shenzhen University, Shenzhen, Guangdong, China
| |
Collapse
|
10
|
McCradden MD, Joshi S, Anderson JA, London AJ. A normative framework for artificial intelligence as a sociotechnical system in healthcare. PATTERNS (NEW YORK, N.Y.) 2023; 4:100864. [PMID: 38035190 PMCID: PMC10682751 DOI: 10.1016/j.patter.2023.100864] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Indexed: 12/02/2023]
Abstract
Artificial intelligence (AI) tools are of great interest to healthcare organizations for their potential to improve patient care, yet their translation into clinical settings remains inconsistent. One of the reasons for this gap is that good technical performance does not inevitably result in patient benefit. We advocate for a conceptual shift wherein AI tools are seen as components of an intervention ensemble. The intervention ensemble describes the constellation of practices that, together, bring about benefit to patients or health systems. Shifting from a narrow focus on the tool itself toward the intervention ensemble prioritizes a "sociotechnical" vision for translation of AI that values all components of use that support beneficial patient outcomes. The intervention ensemble approach can be used for regulation, institutional oversight, and for AI adopters to responsibly and ethically appraise, evaluate, and use AI tools.
Collapse
Affiliation(s)
- Melissa D. McCradden
- Department of Bioethics, The Hospital for Sick Children, Toronto, ON, Canada
- Genetics & Genome Biology Research Program, Peter Gilgan Center for Research & Learning, Toronto, ON, Canada
- Division of Clinical & Public Health, Dalla Lana School of Public Health, Toronto, ON, Canada
| | - Shalmali Joshi
- Department of Biomedical Informatics, Department of Computer Science (Affliate), Data Science Institute, Columbia University, New York, NY, USA
| | - James A. Anderson
- Department of Bioethics, The Hospital for Sick Children, Toronto, ON, Canada
- Institute for Health Policy, Management, and Evaluation, University of Toronto, Toronto, ON, Canada
| | - Alex John London
- Department of Philosophy and Center for Ethics and Policy, Carnegie Mellon University, Pittsburgh, PA, USA
| |
Collapse
|